Creative Medical Technology Holdings, Inc. Debt Conversion, Converted Instrument, Amount
Creative Medical Technology Holdings, Inc. (CELZ) reported Debt Conversion, Converted Instrument, Amount of $153.98 thousand for the 6-month period ending 2021-06-30, per its 10-Q filed 2021-08-16.
Discontinued › Cash Flow › Financing Activities
us-gaap:DebtConversionConvertedInstrumentAmount1 · last filed 2021-08-16
- Creative Medical Technology Holdings, Inc. debt conversion, converted instrument, amount for the quarter ending 2020-03-31 was $1.10M, a 7.20% decline year-over-year.
- Creative Medical Technology Holdings, Inc. debt conversion, converted instrument, amount for the quarter ending 2019-12-31 was $433.43K, a 63.16% decline year-over-year.
- Creative Medical Technology Holdings, Inc. debt conversion, converted instrument, amount for the quarter ending 2019-09-30 was $1.48M, a 69.22% decline year-over-year.
- Creative Medical Technology Holdings, Inc. debt conversion, converted instrument, amount for the quarter ending 2019-06-30 was $1.06M, a 70.86% decline year-over-year.
- Creative Medical Technology Holdings, Inc. debt conversion, converted instrument, amount for fiscal 2019 was $4.16M, a 63.84% decline from fiscal 2018.
- Creative Medical Technology Holdings, Inc. debt conversion, converted instrument, amount for fiscal 2018 was $11.50M, a 3560.48% increase from fiscal 2017.
- Creative Medical Technology Holdings, Inc. debt conversion, converted instrument, amount for fiscal 2017 was $314.07K.
- Creative Medical Technology Holdings, Inc. debt conversion, converted instrument, amount for fiscal 2016 was $0.00.
| Period end | Debt Conversion, Converted Instrument, Amount 3 month | Debt Conversion, Converted Instrument, Amount 6 month | Debt Conversion, Converted Instrument, Amount 9 month | Debt Conversion, Converted Instrument, Amount 12 month |
|---|---|---|---|---|
| 2021-06-30 | $153.98K 10-Q · filed 2021-08-16 | |||
| 2020-09-30 | $40.00K 10-Q · filed 2020-11-13 | |||
| 2020-03-31 | $1.10M 10-Q · filed 2020-05-15 | $1.54M derived: sum of 2 quarters · filed 2020-05-15 | $3.02M derived: sum of 3 quarters · filed 2020-05-15 | $4.07M derived: sum of 4 quarters · filed 2020-05-15 |
| 2019-12-31 | $433.43K derived: 10-K 12 month − 10-Q 9 month · filed 2020-04-06 | $1.91M derived: sum of 2 quarters · filed 2020-04-06 | $2.97M derived: sum of 3 quarters · filed 2020-04-06 | $4.16M 10-K · filed 2020-04-06 |
| 2019-09-30 | $1.48M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-14 | $2.54M derived: sum of 2 quarters · filed 2019-11-14 | $3.72M 10-Q · filed 2019-11-14 | $4.90M derived: sum of 4 quarters · filed 2020-05-15 |
| 2019-06-30 | $1.06M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-13 | $2.24M 10-Q · filed 2019-08-13 | $3.42M derived: sum of 3 quarters · filed 2020-05-15 | $8.23M derived: sum of 4 quarters · filed 2020-05-15 |
| 2019-03-31 | $1.19M 10-Q · filed 2020-05-15 | $2.36M derived: sum of 2 quarters · filed 2020-05-15 | $7.17M derived: sum of 3 quarters · filed 2020-05-15 | $10.80M derived: sum of 4 quarters · filed 2020-05-15 |
| 2018-12-31 | $1.18M derived: 10-K 12 month − 10-Q 9 month · filed 2020-04-06 | $5.99M derived: sum of 2 quarters · filed 2020-04-06 | $9.61M derived: sum of 3 quarters · filed 2020-04-06 | $11.50M 10-K · filed 2020-04-06 |
| 2018-09-30 | $4.81M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-14 | $8.43M derived: sum of 2 quarters · filed 2019-11-14 | $10.32M 10-Q · filed 2019-11-14 | $10.63M derived: sum of 4 quarters · filed 2019-11-14 |
| 2018-06-30 | $3.62M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-13 | $5.51M 10-Q · filed 2019-08-13 | $5.83M derived: sum of 3 quarters · filed 2019-08-13 | $5.83M derived: sum of 4 quarters · filed 2019-08-13 |
| 2018-03-31 | $1.89M 10-Q · filed 2019-05-20 | $2.20M derived: sum of 2 quarters · filed 2019-05-20 | $2.20M derived: sum of 3 quarters · filed 2019-05-20 | $2.20M derived: sum of 4 quarters · filed 2019-05-20 |
| 2017-12-31 | $314.07K derived: 10-K 12 month − 10-Q 9 month · filed 2019-04-01 | $314.07K derived: sum of 2 quarters · filed 2019-04-01 | $314.07K derived: sum of 3 quarters · filed 2019-04-01 | $314.07K 10-K · filed 2019-04-01 |
| 2017-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-14 | $0.00 derived: sum of 2 quarters · filed 2018-11-14 | $0.00 10-Q · filed 2018-11-14 | |
| 2017-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-14 | $0.00 10-Q · filed 2018-08-14 | ||
| 2017-03-31 | $0.00 10-Q · filed 2018-08-03 | |||
| 2016-12-31 | $0.00 10-K · filed 2018-03-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AIM ImmunoTech Inc. (AIM) | United States | $0.006B | |
| CERO THERAPEUTICS HOLDINGS, INC. (CERO) | United States | $0.007B | |
| PharmaCyte Biotech, Inc. (PMCB) | United States | $0.005B | |
| TScan Therapeutics, Inc. (TCRX) | United States | $0.008B | -1.23 |
| WINDTREE THERAPEUTICS INC /DE/ (WINT) | United States | $0.003B | -0.32 |
| VivoSim Labs, INC. (VIVS) | United States | $0.003B | |
| Calidi Biotherapeutics, Inc. (CLDI) | United States | $0.003B | |
| CURIS INC (CRIS) | United States | $0.002B | -0.05 |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |
| Silexion Therapeutics Corp (SLXN) | $0.001B |